Hep C News

Hepatitis C in the News


EASL 2015 HCV Vaccine Lecture: Dr T. Baumert

Posted on April 29, 2015

  Please click here to view this important EASL 2015 HCV presentation by Thomas F. Baumert, MD. Thomas F. Baumert, MD is Professor of Medicine, head of Inserm Research Unit U1110, Institute of Viral and Liver Diseases, head of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Physician at the Center for Digestive Disease and Hepatology at the Strasbourg University Hospitals. He received his MD from the ...

Read More


New peer-reviewed, full-text, free HCV articles

Posted on April 28, 2015

See below for a list of new peer-reviewed, full-text, free HCV articles, available free for a limited time, only in our American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com) New peer-reviewed, full-text article in the section of our Resource Center focused toward Primary Care Providers  Internal PubMed link provided for you to review the abstract only, please visit the American Journal of Medicine Hepatitis ...

Read More


HCV Research Discussion: Dr. Alexander Ploss

What are your interests in the field of HCV Research? My lab is interested in understanding what makes hepatitis C virus (HCV) a virus that infects basically only humans or chimpanzees. There are fairly basic questions that surround the host tropism of the virus, and we want to get a better understanding of the biology, how the virus interacts with its host cell, and also to use this knowledge to build animal models that you could employ to ...

Read More


EASL Congress HCV Interview: Dr E. Lebovics

Regarding studies that are ongoing, what are you most excited about seeing at EASL? The results of which studies and what types of studies? Dr. Lebovics: Well, now that we are able to eliminate hepatitis C with all oral regimens in about 95% of standard patients, one area of great interest is extending our currently available regimens to special populations, specifically those with decompensated cirrhosis, post-transplant and renal failure. ...

Read More


EASL Abstract Highlights – Dr T. Baumert

Posted on April 21, 2015

EASL Abstract O027 The Expression of Tumor Suppressor PTPRD is Down-Regulated in the Liver of Patients With HCV Infection and in Tumor Lesions of Patients With Hepatocellular Carcinoma Van Renne, F.H.T. Duong, C. Gondeau, D. Calabrese, N. Fontaine, A. Ababsa, S.C. Durand, P. Pessaux, M.H. Heim, T.F. Baumert, J. Lupberger. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, ...

Read More


EASL Pre-Congress HCV Interview: Dr R. Brown

Posted on April 20, 2015

Is there any data that is going to be presented at EASL that you’re really excited about? Are there any research studies that are going on right now that you’re really excited about? Dr. Brown: Right now we have two excellent FDA approved options for our genotype 1 Hepatitis C patient, but we have issues with patients who are not genotype 1, or those who have other extenuating circumstances or special populations, for whom we don’t know ...

Read More


EASL Pre-Congress HCV Interview: Dr P. Gaglio

Posted on April 19, 2015

What are your thoughts on birth cohort screening for hepatitis C? Should it be mandated by law? Dr. Gaglio: Sure, well I think that birth-cohort screening is an absolutely forward progress in terms of the screening of Hepatitis C, largely due to the fact that risk-based screening has been very ineffective. So, [birth-cohort screening] has been mandated by law and the problem becomes how do you police that. So, clearly in the state of New York ...

Read More


EASL 2015 Hepatitis Abstract Choices: Dr. Ploss

For more information on the selected EASL 2015 Hepatitis abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G09 Targeting a Host-Cell Entry Factor Barricades Antiviral Resistant HCV Variants From On-Therapy Breakthrough In Human-Liver Mice Vercauteren K et al. The International Liver Congress™ 2015, 50th annual meeting of the European ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Gaglio

Posted on April 16, 2015

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G15 The Association of Sofosbuvir and Daclatasvir For Treating Severe Recurrence of HCV Infection After Liver Transplantation: Results From a Large French Prospective Multicentric ANRS CO23 CUPILT Cohort Coilly A, et al. The International ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Lebovics

Posted on April 16, 2015

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Current agents in special populations Abstract G02 Ledipasvir/Sofosbuvir with Ribavirin is Safe And Efficacious in Decompensated and Post Liver Transplantation Patients with HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial M...

Read More